Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients

Hypertension Research

Volumn 31, Issue 6, 2008, Pages 1163-1170

  Mikami, Satoshi ^a   Hamano, Takayuki ^a   Fujii, Naohiko ^b   Nagasawa, Yasuyuki ^a   Isaka, Yoshitaka ^a   Moriyama, Toshiki ^a   Matsuhisa, Munehide ^a   Ito, Takahito ^a   Imai, Enyu ^a   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

Coronary artery calcification score; Diabetic nephropathy; Fetuin A 2 HS glycoprotein; Osteoprotegerin

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CHOLESTEROL; FETUIN A; HEMOGLOBIN A1C; INTERLEUKIN 6; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTERY CALCIFICATION; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BONE DENSITY; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT TOOL; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIFICATION SCORE; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; RENAL REPLACEMENT THERAPY; RISK FACTOR; SCREENING TEST; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CALCINOSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPROTEGERIN; RENAL DIALYSIS; RISK FACTORS;

EID: 48349108633     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1163     Document Type: Article

References (39)

1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663.
2. Rumberger JA, Brundage BH, Rader DJ, Kondos G: Electron beam computed tomographiic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999; 74: 243-252.
3. Nitta K, Akiba T, Suzuki K, et al: Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004; 27: 527-533.
4. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
5. Sinnott B, Syed I, Sevrukov A, Barengolts E: Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int 2006; 78: 195-202.
6. Godsland IF, Elkeles RS, Feher MD, et al, PREDICT Study Group: Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in type 2 diabetes: the Prospective Evaluation of Diabetic Ischaemic Heart Disease by Coronary Tomography (PREDICT) Study. Diabet Med 2006; 23: 1192-1200.
7. Jono S, Shioi A, Ikari Y, Nishizawa Y: Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006; 24: 176-181.
8. Moe S, Drueke T, Cunningham J, et al: Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KD1GO). Kidney Int 2006; 69: 1945-1953.
9. Mehrotra R, Budoff M, Christenson P, et al: Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int 2004; 66: 2022-2031.
10. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE: Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030.
11. Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H: Vascular calcification and osteoporosis - from clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259.
12. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA: Fetuin-A and kidney function in persons with coronary artery disease - data from the Heart and Soul Study. Nephrol Dial Transplant 2006; 21: 2144-2151.
13. Mehrotra R, Westenfeld R, Christenson P, et al: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67: 1070-1077.
14. Ix JH, Shlipak MG, Samak MJ, et al: Fetuin-A is not associated with mortality in chronic kidney isease. Kidney Int 2007; 72: 1394-1399.
15. K/DOQ1 clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
16. Levey AS, Coresh J, Greene T, et al: Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
17. Shemesh J, Apter S, Rozenman J, et al: Calcification of coronary arteries: detection and quantification with double-helix CT. Radiology 1995; 197: 779-783.
18. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436.
19. Kramer H, Toto R, Peshock R, Cooper R, Victor R: Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513.
20. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
21. Min H, Morony S, Sarosi I, et a;: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenosis. J Exp Med 2000; 192: 463-474.
22. Schoppet M, Al-Fakhri N, Franke FE, et al: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104-4112.
23. Kiechl S, Schett G, Wenning G, et al: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 2004; 109: 2175-2180.
24. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857.
25. Yano K, Tsuda E, Washida N, et al: Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527.
26. Kazama JJ: Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 2004; 13: 411-415.
27. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W: The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789-20796.
28. Kazama JJ, Gejyo F, Ei I: The immunohistochemical localization of alpha2-Heremans-Schmid glycoprotein/fetuin-A (AHSG). Nephrol Dial Transplant 2005; 20: 851-852.
29. Schafer C, Heiss A, Schwarz A, et al: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366.
30. Reynolds JL, Skepper JN, McNair R, et al: Multifunctional roles for serum protein fetuin-A inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930.
31. Katteler M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A (AHSG) concentration in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833.
32. Mehrotra R: Emerging role for fetula-A as constributor to morbidity and mortality in chronic kidney disease. Kidney Int 2007; 72: 137-140.
33. Mathews ST, Singh GP, Ranalletta M, et al: Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 2002; 51: 2450-2458.
34. Price PA, Nguyen TM, Williamson MK: Biochemical characterization of the serum fetuin-mineral complex. J Biol Chem 2003; 278: 22153-22160.
35. Hofbauer LC, Shui C, Riggs BL, et al: Effects of immuno-suppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280: 334-339.
36. 2-induced, NF-kB-dependent survival factor for endothelial cells. J Biol Chem 2000; 275: 20959-20967.
37. Orita Y, Yamamoto H, Kohno N, et al: Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol 2007; 17: 2058-2064.
38. Avram MM, Mittman N, Bonomini L. Chattopadhyay J, Fein P: Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis 1995;36:209-219.
39. Nishizawa Y, Shoji T, Ishimura E, Isaba M, Morii H: Paradox of risk factors for cardiovasculAr mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 2001; 38: S47-S7.